ReviewEndocrine connections2026
Bone turnover marker rhythmicity: implications for osteoporosis treatment and fracture healing.
Review in Endocrine connections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abstract: Bone turnover is a dynamic process with markers of bone turnover displaying varying degrees of rhythmicity. The objective of this narrative review was to synthesize current evidence on the regulation of bone turnover marker (BTM) rhythmicity and to evaluate how these rhythms may influence clinically relevant outcomes in osteoporosis treatment and fracture healing. Structured literature searches were conducted in PubMed to identify studies that examined BTM rhythmicity, intrinsic versus extrinsic factors that influence this rhythmicity, and timing effects of osteoporosis medications and fracture-related healing to inform this narrative review. The reviewed evidence demonstrates that markers of bone resorption exhibit robust diurnal rhythms, whereas bone formation markers show lower-amplitude and more variable oscillations. These rhythms are primarily circadian driven and influenced by environmental factors (e.g. fasting) and have important implications for accurate use and interpretation when used clinically and in research. Clinical and preclinical studies further indicate that the administration time of some osteoporosis medications can influence efficacy and safety, with certain anabolic and antiresorptive agents showing differences in biochemical or structural responses depending on administration time, while others appear timing insensitive or remain unstudied. Emerging experimental data suggest that fracture healing may also display rhythmicity and be differentially impacted by the timing of interventions. Plain language summary: This review summarizes how bone turnover marker levels vary across the day and night and how this rhythmicity may influence the effects of some medications, with implications for optimal use of these markers in clinical practice and research to improve osteoporosis treatment and potentially fracture healing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.